• Takeda Pharmaceutical (NYSE:TAK) has inked a collaboration agreement with privately held Alloy Therapeutics to develop the former's proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK).
• The companies noted that the paternship will help Alloy develop therapies to treat solid and hematological malignancies.
• A news release noted that iCAR-T "has potential to develop 'off-the-shelf' cell therapies, offering the potential for best-in-class performance with enhanced potency, and significantly lower manufacturing costs compared to autologous cell therapy."
• Terms call for Alloy to receive co-exclusive rights to commercialize iCAR-T and iCAR-NK products for oncology indications. Also, the company wll use its exisiting expertise to advance the iCAR-T/NK platforms and provide broader access to the technology for future partners.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.